1997
Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study
MCDOUGLE C, HOLMES J, BRONSON M, ANDERSON G, VOLKMAR F, PRICE L, COHEN D. Risperidone Treatment of Children and Adolescents With Pervasive Developmental Disorders: A Prospective, Open-Label Study. Journal Of The American Academy Of Child & Adolescent Psychiatry 1997, 36: 685-693. PMID: 9136504, DOI: 10.1097/00004583-199705000-00020.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderDevelopmental disordersRisperidone treatmentClinical Global Impression ScaleOpen-label studyOpen-label trialPlacebo-controlled studyCommon side effectsEfficacy of risperidoneShort-term safetyGlobal Impression ScaleGlobal improvement itemBehavioral ratingsChildhood disintegrative disorderSocial relatednessTreatment of childrenAsperger's disorderRepetitive behaviorsAutistic disorderBehavioral symptomsBaseline visitMean ageImpression ScaleAdolescentsOptimal dose
1992
Clomipramine in Autism: Preliminary Evidence of Efficacy
MCDOUGLE C, PRICE L, VOLKMAR F, GOODMAN W, WARD-O'BRIEN D, NIELSEN J, BREGMAN J, COHEN D. Clomipramine in Autism: Preliminary Evidence of Efficacy. Journal Of The American Academy Of Child & Adolescent Psychiatry 1992, 31: 746-750. PMID: 1644740, DOI: 10.1097/00004583-199207000-00025.Peer-Reviewed Original ResearchConceptsAutistic disorderPreliminary evidenceObsessive-compulsive symptomsSocial relatednessImpulsive behaviorCompulsive symptomsEfficacy of clomipramineYoung adultsPrevious evidenceClomipramine treatmentSerotonin neurotransmissionDisordersAutismClomipramineSymptomsTreatmentEfficacySignificant improvementAdultsEvidenceOutpatientsPathophysiologyNeurotransmissionRelatednessFindings